Literature DB >> 26295815

Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo.

Resham Chhabra, Barbara Ruozi, Antonietta Vilella, Daniela Belletti, Katharina Mangus, Stefanie Pfaender, Tasnuva Sarowar, Tobias Maria Boeckers, Michele Zoli, Flavio Forni, Maria Angela Vandelli, Giovanni Tosi, Andreas Martin Grabrucker1.   

Abstract

A dyshomeostasis of zinc ions has been reported for many psychiatric and neurodegenerative disorders including schizophrenia, attention deficit hyperactivity disorder, depression, autism, Parkinson's and Alzheimer's disease. Furthermore, alterations in zinc-levels have been associated with seizures and traumatic brain injury. Thus, altering zinclevels within the brain is emerging as a new target for the prevention and treatment of psychiatric and neurological diseases. However, given the restriction of zinc uptake into the brain by the blood-brain barrier, methods for controlled regulation and manipulation of zinc concentrations within the brain are rare. Here, we performed in vivo studies investigating the possibility of brain targeted zinc delivery using zinc-loaded nanoparticles which are able to cross the blood-brain barrier. After injecting these nanoparticles, we analyzed the regional and time-dependent distribution of zinc and nanoparticles within the brain. Moreover, we evaluated whether the presence of zinc-loaded nanoparticles alters the expression of zinc sensitive genes and proteins such as metallothioneins and zinc transporters and quantified possible toxic effects. Our results show that zinc loaded g7 nanoparticles offer a promising approach as a novel non - invasive method to selectively enrich zinc in the brain within a small amount of time.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26295815     DOI: 10.2174/1871527314666150821111455

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  3 in total

Review 1.  Synaptic Zn2+ and febrile seizure susceptibility.

Authors:  Christopher A Reid; Michael S Hildebrand; Saul A Mullen; Joanne M Hildebrand; Samuel F Berkovic; Steven Petrou
Journal:  Br J Pharmacol       Date:  2016-11-28       Impact factor: 8.739

2.  Prospects of Zinc Supplementation in Autism Spectrum Disorders and Shankopathies Such as Phelan McDermid Syndrome.

Authors:  Simone Hagmeyer; Ann Katrin Sauer; Andreas M Grabrucker
Journal:  Front Synaptic Neurosci       Date:  2018-05-23

3.  Dietary zinc supplementation rescues fear-based learning and synaptic function in the Tbr1+/- mouse model of autism spectrum disorders.

Authors:  Kevin Lee; Yewon Jung; Yukti Vyas; Imogen Skelton; Wickliffe C Abraham; Yi-Ping Hsueh; Johanna M Montgomery
Journal:  Mol Autism       Date:  2022-03-18       Impact factor: 7.509

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.